Hemostemix (HEM) Stock Price, News & Analysis

Company Overview

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Key Stats

• Today's Range: C$0.06 to C$0.06
• 50-Day Range: C$0.06 to C$0.08
• 52-Week Range: C$0.04 to C$0.11
• Volume: 251,949 shs
• Average Volume: 43,836 shs
• Market Capitalization: C$12.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: CVE:HEM
• CIK: N/A
• Web: www.hemostemix.com
• Phone: +1-403-3409207
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$5.00 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: 92.37%
• Return on Assets: -349.24%

Debt

• Debt-to-Equity Ratio: -61.85
• Current Ratio: 0.13
• Quick Ratio: 0.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 10.77
• Book Value: C($0.03) per share
• Price / Book: -2.13

Miscellaneous

• Outstanding Shares: 211,441,000
• Free Float: N/A
• Market Cap: C$12.69 million
• Optionable: Not Optionable
• Beta: 0.50